文献速递糖尿病骨质疏松与钙磷/甲状旁腺肥胖与代谢综合征

维生素D3补充对无高糖尿病风险的健康老年人2型糖尿病发病率的影响(FIND):一项随机对照试验

The effect of vitamin D3 supplementation on the incidence of type 2 diabetes in healthy older adults not at high risk for diabetes (FIND): a randomised controlled trial.
PubMed 文献 · Diabetologia · 2024-12-02

FIND试验在2271名无心血管疾病或癌症且未使用降糖药的≥60岁男性及≥65岁女性中比较安慰剂、维生素D3 1600 IU/日或3200 IU/日对2型糖尿病发病率的影响。平均随访4.2年,各组的2型糖尿病事件分别为38例(5.0%)、31例(4.2%)和36例(4.7%),与安慰剂相比的HR分别为0.81(95%CI 0.50,1.30)和0.92(95%CI 0.58,1.45),p-trend=0.73。结论认为在无高糖尿病风险且血清25(OH)D3水平足以维持骨骼健康的健康老年人中,维生素D3补充未显著降低糖尿病发病风险。

要点

  • 在无高糖尿病风险的健康老年人中,维生素D3 1600 IU/日或3200 IU/日与安慰剂相比未显著降低2型糖尿病发病风险。
  • 按BMI分层,联合维生素D3组与安慰剂组相比的HR在<25、25-30和≥30 kg/m2组分别为0.43、0.97和1.00(p-interaction<0.001)。
  • 亚队列中补充12个月后,安慰剂组、1600 IU/日组和3200 IU/日组的血清25(OH)D3浓度分别为72.6、99.3和120.9 nmol/l。

核心结论

  • 在无高糖尿病风险且血清25(OH)D3水平足以维持骨骼健康的健康老年人中,维生素D3补充未显著降低2型糖尿病发病风险。

研究设计与样本

  • FIND为5年随机安慰剂对照平行臂试验,纳入2271名≥60岁男性及≥65岁女性,来自一般芬兰人群,无心血管疾病或癌症且未使用糖尿病药物。
  • 研究设三个臂:安慰剂、维生素D3 1600 IU/日或3200 IU/日;由非研究组统计师按性别分层以1:1:1比例简单随机化,基于计算机随机数生成。
  • 参与者、研究者和研究人员对分组设盲;使用国家健康登记处收集事件数据;505名代表性亚队列参与者在第0、6、12和24个月接受详细面对面检查。

主要发现

  • 平均随访4.2年,安慰剂组(n=760)、1600 IU/日组(n=744)和3200 IU/日组(n=767)的2型糖尿病事件分别为38例(5.0%)、31例(4.2%)和36例(4.7%)。
  • 与安慰剂相比,1600 IU/日组HR为0.81(95%CI 0.50,1.30),3200 IU/日组HR为0.92(95%CI 0.58,1.45),p-trend=0.73。
  • 两个维生素D3组合并后与安慰剂组比较,HR为0.86(95%CI 0.58,1.29)。
  • 按BMI分层(<25 kg/m2 [n=813,事件数=12]、25-30 kg/m2 [n=1032,事件数=38]、≥30 kg/m2 [n=422,事件数=54]),联合维生素D3组与安慰剂组相比的HR分别为0.43(95%CI 0.14,1.34)、0.97(95%CI 0.50,1.91)和1.00(95%CI 0.57,1.75),p-interaction<0.001。
  • 亚队列基线平均(SD)血清25(OH)D3浓度为74.5(18.1)nmol/l;12个月后,安慰剂组、1600 IU/日组和3200 IU/日组的浓度分别为72.6(17.7)、99.3(20.8)和120.9(22.1)nmol/l;24个月随访期间,血浆葡萄糖或胰岛素浓度变化、BMI或腰围均无差异(p值≥0.19)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Vitamin D insufficiency is associated with an elevated risk of type 2 diabetes, but evidence from randomised trials on the benefits of vitamin D supplementation is limited, especially for average-risk populations. The Finnish Vitamin D Trial (FIND) investigated the effects of vitamin D3 supplementation at two different doses on the incidence of type 2 diabetes in a generally healthy older adult population. METHODS: FIND was a 5 year randomised placebo-controlled, parallel-arm trial among 2271 male and female participants aged ≥60 years and ≥65 years, respectively, from a general Finnish population who were free of CVD or cancer and did not use diabetes medications. The study had three arms: placebo, 1600 IU/day of vitamin D3 or 3200 IU/day of vitamin D3. A non-study group statistician carried out sex-stratified simple randomisation in a 1:1:1 ratio, based on computerised random number generation. The participants, investigators and study staff were masked to group assignment. National health registries were used to collect event data. A representative subcohort of 505 participants had more detailed in-person investigations at months 0, 6, 12 and 24. RESULTS: During the mean follow-up of 4.2 years, there were 38 (5.0%), 31 (4.2%) and 36 (4.7%) type 2 diabetes events in the placebo (n=760), 1600 IU/day vitamin D3 (n=744; vs placebo: HR 0.81; 95% CI 0.50, 1.30) and 3200 IU/day vitamin D3 (n=767; vs placebo: HR 0.92, 95% CI 0.58, 1.45) arms, respectively (p-trend=0.73). When the two vitamin D3 arms were combined and compared with the placebo arm, the HR was 0.86 (95% CI 0.58, 1.29). In the analyses stratified by BMI (<25 kg/m2 [n=813, number of type 2 diabetes events=12], 25-30 kg/m2 [n=1032, number of events=38], ≥30 kg/m2 [n=422, number of events=54]), the HRs in the combined vitamin D3 arms vs the placebo were 0.43 (95% CI 0.14, 1.34), 0.97 (0.50, 1.91) and 1.00 (0.57, 1.75), respectively (p-interaction <0.001). In the subcohort, the mean (SD) baseline serum 25-hydroxyvitamin D3 (25(OH)D3) concentration was 74.5 (18.1) nmol/l. After 12 months, the concentrations were 72.6 (17.7), 99.3 (20.8) and 120.9 (22.1) nmol/l in the placebo, 1600 IU/day vitamin D3 and 3200 IU/day vitamin D3 arms, respectively. In the subcohort, no differences were observed in changes in plasma glucose or insulin concentrations, BMI or waist circumference during the 24 month follow-up (p values ≥0.19). CONCLUSION/INTERPRETATION: Among generally healthy older adults who are not at high risk for diabetes and who have serum 25(OH)D3 levels that are sufficient for bone health, vitamin D3 supplementation did not significantly reduce the risk of developing diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT01463813.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Virtanen JK, Hantunen S, Kallio N, et al. The effect of vitamin D3 supplementation on the incidence of type 2 diabetes in healthy older adults not at high risk for diabetes (FIND): a randomised controlled trial. Diabetologia. 2024. PMID: 39621103. doi:10.1007/s00125-024-06336-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。